U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545603) titled 'Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma' on March 26.
Brief Summary: This is a single-arm, open-label, multicenter Phase II clinical study designed to enroll 65 subjects with relapsed or refractory follicular lymphoma (EZH2 wild-type).
The study procedures include a pre-screening phase, screening phase, treatment phase, and follow-up phase.Eligible subjects will enter the treatment phase and receive 1200 mg of XNW5004 tablets twice daily, with a 10-14-hour interval between doses. Each treatment cycle consists of 28 consecutive days of dosing, and pharmacokinetic (PK) blood ...